Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2020

01-08-2020 | Original paper

Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma

Authors: Shuangshuang Mao, Yuan Li, Zhiliang Lu, Yun Che, Jianbing Huang, Yuanyuan Lei, Yalong Wang, Xinfeng Wang, Chengming Liu, Sufei Zheng, Ning Li, Jiagen Li, Nan Sun, Jie He

Published in: Cellular Oncology | Issue 4/2020

Login to get access

Abstract

Purpose

Lung adenocarcinoma (LUAD) is the predominant subtype of lung cancer, with increasing evidence showing clinical benefits of immunotherapy. However, a lack of integrated profiles of complex LUAD immune microenvironments hampers the application of immunotherapy, resulting in limited eligible patient populations as well as drug resistance problems. Here, we aimed to systematically profile the immune signatures of LUADs and to assess the role of the immune microenvironment in patient outcome.

Methods

We systematically profiled the immune signatures of LUADs deposited in the TCGA and GEO databases using a total of 730 immune-related genes. Differential expression analysis was used to identify dysregulated genes. Univariate Cox analysis followed by robust likelihood-based survival analysis and multivariate Cox analysis were applied to construct an immune-related prognostic model.

Results

We found that differentially expressed immune genes were mainly enriched in immune cell proliferation, migration, activation and the NF-κB and TNF signaling pathways. The 10-immune gene predictive model that we constructed could differentiate LUAD patients with different overall survival times in several datasets, with areas under the curve (AUCs) of 0.67, 0.69, 0.72 and 0.74. LUAD patients with high- or low-risk scores exhibited distinct immune cell compositions, which may explain the prognostic significance of our model.

Conclusions

Our results add to the current knowledge of immune processes in LUADs and underscore the critical role of the immune microenvironment in LUAD patient outcome.
Appendix
Available only for authorised users
Literature
1.
W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015. CA Cancer J Clin 66, 115–132 (2016)PubMed
2.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J Clin 68, 7–30 (2018)PubMed
3.
L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108 (2015)PubMed
4.
L. Cortes-Dericks, D. Galetta, The therapeutic potential of mesenchymal stem cells in lung cancer: Benefits, risks and challenges. Cell Oncol 42, 727–738 (2019)
5.
A. Quintanal-Villalonga, S. Molina-Pinelo, Epigenetics of lung cancer: A translational perspective. Cell Oncol 42, 739–756 (2019)
6.
W.D. Travis, E. Brambilla, A.G. Nicholson, Y. Yatabe, J.H.M. Austin, M.B. Beasley, L.R. Chirieac, S. Dacic, E. Duhig, D.B. Flieder, K. Geisinger, F.R. Hirsch, Y. Ishikawa, K.M. Kerr, M. Noguchi, G. Pelosi, C.A. Powell, M.S. Tsao, I. Wistuba, W.H.O. Panel, The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10, 1243–1260 (2015)PubMed
7.
Z. Chen, C.M. Fillmore, P.S. Hammerman, C.F. Kim, K.K. Wong, Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer 14, 535–546 (2014)PubMedPubMedCentral
8.
J. Rotow, T.G. Bivona, Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17, 637–658 (2017)PubMed
9.
10.
A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol 42, 609–626 (2019)
11.
L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, M.C. Garassino, K. Investigators, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378, 2078–2092 (2018)
12.
H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow, E.E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaufl, O. Arrieta, M.A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin, N. Rizvi, L. Crino, G.R. Blumenschein Jr., S.J. Antonia, C. Dorange, C.T. Harbison, F. Graf Finckenstein, J.R. Brahmer, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373, 1627–1639 (2015)PubMedPubMedCentral
13.
J.C.H. Chow, K.M. Cheung, W.C.S. Cho, Atezolizumab in non-small cell lung cancer: The era of precision immuno-oncology. Ann Transl Med 5, 265 (2017)PubMedPubMedCentral
14.
P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A.N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A.J. Gutierrez, T.R. Grogan, C. Mateus, G. Tomasic, J.A. Glaspy, R.O. Emerson, H. Robins, R.H. Pierce, D.A. Elashoff, C. Robert, A. Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)PubMedPubMedCentral
15.
S. Spranger, T.F. Gajewski, Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer 18, 139–147 (2018)PubMedPubMedCentral
16.
R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, H.E. Kohrt, L. Horn, D.P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P.S. Hegde, I. Mellman, D.S. Chen, F.S. Hodi, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014)PubMedPubMedCentral
17.
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S. Ho, Martin L. Miller, Natasha Rekhtman, Andre L. Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher and T.A. Chan, Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348, 124–128 (2016)
18.
D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, L.A. Diaz Jr., PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372, 2509–2520 (2015)PubMedPubMedCentral
19.
H. Tang, Y. Wang, L.K. Chlewicki, Y. Zhang, J. Guo, W. Liang, J. Wang, X. Wang, Y.X. Fu, Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285–296 (2016)PubMedPubMedCentral
20.
S. Zheng, X. Luo, C. Dong, D. Zheng, J. Xie, L. Zhuge, Y. Sun, H. Chen, A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. Int J Cancer 143, 2592–2601 (2018)PubMed
21.
H. Faruki, G.M. Mayhew, J.S. Serody, D.N. Hayes, C.M. Perou, M. Lai-Goldman, Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol 12, 943–953 (2017)PubMedPubMedCentral
22.
M.B. Schabath, E.A. Welsh, W.J. Fulp, L. Chen, J.K. Teer, Z.J. Thompson, B.E. Engel, M. Xie, A.E. Berglund, B.C. Creelan, S.J. Antonia, J.E. Gray, S.A. Eschrich, D.T. Chen, W.D. Cress, E.B. Haura, A.A. Beg, Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35, 3209–3216 (2016)PubMed
23.
Q. Song, J. Shang, Z. Yang, L. Zhang, C. Zhang, J. Chen, X. Wu, Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med 17, 70 (2019)PubMedPubMedCentral
24.
J.K. HyungJun Cho, A. Yu, S. Kim, S.-M. Hong, Robust likelihood-based survival modeling with microarray data. J Statistical Software 29 (2009)
25.
A.M. Newman, C.L. Liu, M.R. Green, A.J. Gentles, W. Feng, Y. Xu, C.D. Hoang, M. Diehn, A.A. Alizadeh, Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12, 453–457 (2015)PubMedPubMedCentral
26.
M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I.M. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, P.-H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J.M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, F. Pontén, Tissue-based map of the human proteome. Science 34, 1260419 (2015)
27.
G. Pascual, A. Avgustinova, S. Mejetta, M. Martin, A. Castellanos, C.S. Attolini, A. Berenguer, N. Prats, A. Toll, J.A. Hueto, C. Bescos, L. Di Croce, S.A. Benitah, Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017)PubMed
28.
A. Ladanyi, A. Mukherjee, H.A. Kenny, A. Johnson, A.K. Mitra, S. Sundaresan, K.M. Nieman, G. Pascual, S.A. Benitah, A. Montag, S.D. Yamada, N.A. Abumrad, E. Lengyel, Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37, 2285–2301 (2018)PubMedPubMedCentral
29.
J. Pan, Z. Fan, Z. Wang, Q. Dai, Z. Xiang, F. Yuan, M. Yan, Z. Zhu, B. Liu, C. Li, CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3beta/beta-catenin pathway. Journal of experimental & clinical cancer research : CR 38, 52 (2019)PubMedCentral
30.
J. Couzin-Frankel, Breakthrough of the year 2013. Cancer immunotherapy Science 342, 1432–1433 (2013)PubMed
31.
A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. von Pawel, S.M. Gadgeel, T. Hida, D.M. Kowalski, M.C. Dols, D.L. Cortinovis, J. Leach, J. Polikoff, C. Barrios, F. Kabbinavar, O.A. Frontera, F. De Marinis, H. Turna, J.-S. Lee, M. Ballinger, M. Kowanetz, P. He, D.S. Chen, A. Sandler, D.R. Gandara, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017)PubMed
32.
E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.J. Ahn, E. Felip, J.S. Lee, M.D. Hellmann, O. Hamid, J.W. Goldman, J.C. Soria, M. Dolled-Filhart, R.Z. Rutledge, J. Zhang, J.K. Lunceford, R. Rangwala, G.M. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi, K. Investigators, Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372, 2018–2028 (2015)
33.
J. Brahmer, K.L. Reckamp, P. Baas, L. Crino, W.E. Eberhardt, E. Poddubskaya, S. Antonia, A. Pluzanski, E.E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Aren Frontera, L. Havel, M. Steins, M.C. Garassino, J.G. Aerts, M. Domine, L. Paz-Ares, M. Reck, C. Baudelet, C.T. Harbison, B. Lestini, D.R. Spigel, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373, 123–135 (2015)PubMedPubMedCentral
34.
W.H. Fridman, F. Pages, C. Sautes-Fridman, J. Galon, The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12, 298–306 (2012)PubMed
35.
36.
S.K. Biswas, A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11, 889 (2010)PubMed
37.
A. Mantovani, S. Sozzani, M. Locati, P. Allavena, A. Sica, Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23, 549–555 (2002)PubMed
38.
A. Salmaninejad, S.F. Valilou, A. Soltani, S. Ahmadi, Y.J. Abarghan, R.J. Rosengren, A. Sahebkar, Tumor-associated macrophages: Role in cancer development and therapeutic implications. Cell Oncol 42, 591–608 (2019)
39.
M. Karin, Y. Cao, F.R. Greten, Z.W. Li, NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2, 301–310 (2002)PubMed
40.
Y. Grinberg-Bleyer, H. Oh, A. Desrichard, D.M. Bhatt, R. Caron, T.A. Chan, R.M. Schmid, U. Klein, M.S. Hayden, S. Ghosh, NF-kappaB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer. Cell 170, 1096, e1013–1108 (2017)PubMedPubMedCentral
41.
K. Taniguchi, M. Karin, NF-kappaB, inflammation, immunity and cancer: Coming of age. Nat Rev Immunol 18, 309–324 (2018)PubMed
42.
R.L. Silverstein and M. Febbraio, CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2, re3 (2009)
43.
T.K. Means, E. Mylonakis, E. Tampakakis, R.A. Colvin, E. Seung, L. Puckett, M.F. Tai, C.R. Stewart, R. Pukkila-Worley, S.E. Hickman, K.J. Moore, S.B. Calderwood, N. Hacohen, A.D. Luster, J. El Khoury, Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med 206, 637–653 (2009)PubMedPubMedCentral
44.
By Matthew L. Albert, S. Frieda A., Pearce, Loise M. Francisco, Birthe Sauter, Pampa Roy, Roy L. Silverstein and N. Bhardwaj, immature dendritic cells phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188, 1359–1368 (1998)
45.
Q. Sun, W. Zhang, L. Wang, F. Guo, D. Song, Q. Zhang, D. Zhang, Y. Fan, J. Wang, Hypermethylated CD36 gene affected the progression of lung cancer. Gene 678, 395–406 (2018)PubMed
46.
R.A. DeFilippis, H. Chang, N. Dumont, J.T. Rabban, Y.Y. Chen, G.V. Fontenay, H.K. Berman, M.L. Gauthier, J. Zhao, D. Hu, J.J. Marx, J.A. Tjoe, E. Ziv, M. Febbraio, K. Kerlikowske, B. Parvin, T.D. Tlsty, CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov 2, 826–839 (2012)PubMedPubMedCentral
47.
X. Zhang, J. Yao, H. Shi, B. Gao, L. Zhang, LncRNA TINCR/microRNA-107/CD36 regulates cell proliferation and apoptosis in colorectal cancer via PPAR signaling pathway based on bioinformatics analysis. Biol Chem 400, 663–675 (2019)PubMed
48.
A. Nath, C. Chan, Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep 6, 18669 (2016)PubMedPubMedCentral
49.
H.L. Huang, Y.C. Wu, L.J. Su, Y.J. Huang, P. Charoenkwan, W.L. Chen, H.C. Lee, W.C. Chu, S.Y. Ho, Discovery of prognostic biomarkers for predicting lung cancer metastasis using microarray and survival data. BMC Bioinformatics 16, 54 (2015)PubMedPubMedCentral
50.
D.E. Johnson, R.A. O'Keefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15, 234–248 (2018)PubMedPubMedCentral
51.
G. Srikrishna, S100A8 and S100A9: New insights into their roles in malignancy. J Innate Immun 4, 31–40 (2012)PubMed
52.
F. Shabani, A. Farasat, M. Mahdavi, N. Gheibi, Calprotectin (S100A8/S100A9): A key protein between inflammation and cancer. Inflamm Res 67, 801–812 (2018)PubMed
53.
G.E. White, A.J. Iqbal, D.R. Greaves, CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol Rev 65, 47–89 (2013)PubMed
54.
U.H. Weidle, S. Klostermann, D. Eggle, A. Kruger, Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 7, 287–302 (2010)PubMed
55.
H. Nakamura, S. Dan, T. Akashi, M. Unno, T. Yamori, Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR. Biol Pharm Bull 30, 1181–1184 (2007)PubMed
56.
K. Liu, K. Yang, B. Wu, H. Chen, X. Chen, X. Chen, L. Jiang, F. Ye, D. He, Z. Lu, L. Xue, W. Zhang, Q. Li, Z. Zhou, X. Mo, J. Hu, Tumor-infiltrating immune cells are associated with prognosis of gastric cancer. Medicine (Baltimore) 94, e1631 (2015)
57.
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Page’s, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P-H. Cugnenc, Z. Trajanoski, W-H. Fridman, F. Page’s, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006)
58.
M.R. Tian Tian, Wentao Yang, Ruohong Shui. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget 7, 27323808 (2016)
59.
E. Brambilla, G. Le Teuff, S. Marguet, S. Lantuejoul, A. Dunant, S. Graziano, R. Pirker, J.Y. Douillard, T. Le Chevalier, M. Filipits, R. Rosell, R. Kratzke, H. Popper, J.C. Soria, F.A. Shepherd, L. Seymour, M.S. Tsao, Prognostic effect of tumor lymphocytic infiltration in Resectable non-small-cell lung cancer. J Clin Oncol 34, 1223–1230 (2016)PubMedPubMedCentral
60.
D. Argyle, T. Kitamura, Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors. Front Immunol 9, 2629 (2018)PubMedPubMedCentral
61.
C.E.M. Aarts and T.W. Kuijpers, Neutrophils as myeloid-derived suppressor cells. Eur J Clin Invest 48 Suppl 2, e12989 (2018)
62.
J. Borst, T. Ahrends, N. Babala, C.J.M. Melief, W. Kastenmuller, CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18, 635–647 (2018)PubMed
Metadata
Title
Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma
Authors
Shuangshuang Mao
Yuan Li
Zhiliang Lu
Yun Che
Jianbing Huang
Yuanyuan Lei
Yalong Wang
Xinfeng Wang
Chengming Liu
Sufei Zheng
Ning Li
Jiagen Li
Nan Sun
Jie He
Publication date
01-08-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00515-7

Other articles of this Issue 4/2020

Cellular Oncology 4/2020 Go to the issue

Original paper

IL-17A and IL-17F orchestrate macrophages to promote lung cancer

Original paper

Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level

Review

Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles

Review

Functional and metabolic targeting of natural killer cells to solid tumors

Original paper

Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations

Original paper

LINC00858 knockdown inhibits gastric cancer cell growth and induces apoptosis through reducing WNK2 promoter methylation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits